Abbisko Cayman Company Description

Abbisko Cayman Limited engages in the discovering and developing small molecule oncology therapies in China.

The company develops pimicotinib, which is in Phase III clinical trial for treatment of tenosynovial giant cell tumor; Irpagratinib that is in Phase II clinical trial for treatment of liver cancer; Fexagratinib, which is in Phase II clinical trial for the treatment of urothelial carcinoma; ABSK043 that is in Phase I clinical trial for treatment of multiple tumors; ABSK061, ABSK121, and ABSK051, which is in Phase I clinical trial for treatment of solid tumors; ABSK112 that is in Phase I of clinical trial for treatment of non-small cell lung cancer; ABSK012, which is in Phase I clinical trial for treatment of soft tissue sarcoma.

It is involved in technical services and consultation. The company was founded in 2016 and is headquartered in Shanghai, the People’s Republic of China.

Abbisko Cayman Limited

Country	Cayman Islands
Founded	2016
Industry	Biotechnology
Sector	Healthcare
Employees	258
CEO	Yao-Chang Xu

Contact Details

Address: Building 1, 12Bth floor Shanghai China
Phone	86 21 6891 1058
Website	abbisko.com

Stock Details

Ticker Symbol	2256
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	KYG0028A1085
SIC Code	2836

Key Executives

Name	Position
Dr. Yao-Chang Xu	Founder, Chairman of the Board and Chief Executive Officer
Dr. Hongping Yu	Co-Founder, Jt Co Secretary, Senior Vice President of Chemistry, Chief Scientific Officer and Executive Director
Dr. Zidong Zhang	Chief Financial Officer
Jia Feng	Vice President of Human Resources and Operations and Head of Human Resource
Yongyi Li	General Counsel
Dr. Zhen Zhang	Vice President of CMC and Head of Chemistry, Manufacturing and Controls
Dr. Jing Ji	Chief Medical Officer and Executive Director
Yin Wah Chan FCCA, FCIS, FCS, HKICS	Joint Company Secretary